Original Article
DOI: 10.1159/000368312

Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions

Düriye S. Karagöz Özen Mehmet A. Ozturk Övgü Aydin Zeynep H. Turna Sennur Ilvan Mustafa Özgüroglu
Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

Table 1. Patient characteristics of the study population

Properties		Properties	
Age – median months (range)	48.5 (30–77)	**Metastatic biopsy region**	**n (%)**
Sex	**n (%)**	Skin	13 (22.4)
Female	56 (96.6)	Lung	13 (22.4)
Male	2 (3.4)	Bone	7 (12.1)
Primary tumor histology	**n (%)**	Brain	3 (5.2)
Invasive ductal	46 (79.3)	Liver	3 (5.2)
Invasive lobular	4 (6.9)	Ovary	1 (1.7)
Inflammatory	1 (1.7)	Other	17 (29.3)
Mix	5 (8.6)	**Biopsy material**	**n (%)**
Other	2 (3.4)	Tissue	44 (78.6)
Stage	**n (%)**	Cell aspiration	12 (21.4)
Stage 1	6 (10.3)	**Hormonal therapy**	**n (%)**
Stage 2	20 (34.5)	Adjuvan	27 (61.37)
Stage 3	19 (32.8)	Metastatic	17 (38.63)
Stage 4	11 (19)	**Trastuzumab**	**n (%)**
Type of tumor resection	**n (%)**	Yes	11 (18.96)
Modified radical mastectomy	35 (68.6)	No	47 (81.04)
Breast conserving surgery	16 (31.4)	**Radiotherapy**	**n (%)**
		Adjuvant	26 (63.64)
		Palliative	16 (36.36)

Table 3. Patients with HR status change between primary and metastatic tumors

Patient	ER – p	ER – m	PR – p	PR – m	Do the results affect hormone treatment plan on BC progression?
Case # 1	3+	0	3+	0	Yes
Case # 2	3+	0	0	0	Yes
Case # 3	3+	0	2+	0	Yes
Case # 4	2+	0	2+	0	Yes
Case # 5	2+	0	2+	0	Yes
Case # 6	1+	0	2+	0	Yes
Case # 7	0	3+	0	0	Yes
Case # 8	0	2+	0	3+	Yes
Case # 9	0	3+	0	3+	Yes
Case # 10	0	1+	0	1+	Yes
Case # 11	0	0	1+	0	Yes
Case # 12	3+	3+	0	1+	No
Case # 13	3+	2+	3+	0	No
Case # 14	3+	2+	3+	0	No
Case # 15	3+	1+	3+	0	No
Case # 16	3+	3+	3+	0	No
Case # 17	3+	2+	3+	0	No
Case # 18	3+	1+	3+	0	No
Case # 19	3+	1+	3+	0	No
Case # 20	2+	3+	3+	0	No
Case # 21	2+	3+	3+	0	No
Case # 22	3+	1+	2+	0	No
Case # 23	3+	1+	1+	0	No
Case # 24	3+	1+	1+	0	No
Case # 25	3+	1+	1+	0	No
Case # 26	3+	3+	1+	0	No
Case # 27	2+	3+	1+	0	No

ER-p; estrogen receptor status of primary tumor, ER-m; estrogen receptor status of metastatic tumor, PR-p; progesterone receptor status of primary tumor, PR-m; progesterone receptor status of metastatic tumor.



Figure 2. Survival according to hormone receptor expression discrepancy between primary and metastatic tumors.



Figure 3: Survival according to HER-2 expression discrepancy between primary and metastatic tumors.